Predicting factors for locoregional failure of high-dose-rate brachytherapy for early-stage oral cancer

被引:0
|
作者
Petera, Jiri [1 ]
Sirak, Igor [1 ]
Tucek, Lubos [2 ]
Hodek, Miroslav [1 ]
Paluska, Petr [1 ]
Kasaova, Linda [1 ]
Paulikova, Simona [1 ]
Vosmik, Milan [1 ]
Dolezalova, Helena [2 ]
Cvanova, Michaela [3 ]
Halamka, Magdalena [5 ]
Laco, Jan [4 ]
机构
[1] Univ Hosp Hradec Kralove, Dept Oncol & Radiotherapy, Hradec Kralove 50005, Czech Republic
[2] Univ Hosp Hradec Kralove, Dept Stomatol, Hradec Kralove 50005, Czech Republic
[3] Masaryk Univ, Inst Biostat & Anal, Brno, Czech Republic
[4] Univ Hosp Hradec Kralove, Fingerland Dept Pathol, Hradec Kralove 50005, Czech Republic
[5] Univ Hosp Hradec Kralove, Dept Oncol, Hradec Kralove 50005, Czech Republic
关键词
high-dose-rate brachytherapy; oral cancer; predictive factors; VEGF; SQUAMOUS-CELL CARCINOMA; POSTOPERATIVE BRACHYTHERAPY; NODE METASTASIS; EXPRESSION; TONGUE; HEAD; RADIOTHERAPY; ANGIOGENESIS; PROGNOSIS; SURVIVAL;
D O I
10.2217/PME.12.95
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: Brachytherapy is an alternative to surgery in the treatment of the early stages of oral tongue cancer. The aim of this retrospective study was to analyze the clinical risk factors and possible candidate biomarkers of local and regional tumor control. Patients & methods: Twenty-four patients were treated between the years 2001 and 2010. Median follow-up was 37.4 months. Correlation between disease-free survival and clinical stage, tumor grade, resection margin, depth of invasion, and p16, EGF receptor, NE-kappa B, HIF-1 alpha, HER2, Ku-80, COX-2 and VEGF expression was evaluated. Results: The estimated 5-year local control was 81% and locoregional control was 62%. Depth of tumor invasion (p = 0.018) and higher VEGF expression (p = 0.016) were significantly predictive for worse disease-free survival in Cox multivariate analysis. Conclusion: Intensity of VEGF expression and depth of tumor invasion may be significantly negative predictors of disease-free survival in tongue cancer patients treated by brachytherapy alone. Predictive value of VEGF deserves evaluation in larger studies.
引用
收藏
页码:879 / 887
页数:9
相关论文
共 50 条
  • [1] The impact of modern preoperative high-dose-rate brachytherapy in early-stage cervical cancer
    Cagetti, Leonel Varela
    Gonzague-Casabianca, Laurence
    Zemmour, Christophe
    Lambaudie, Eric
    Houvenaeghel, Gilles
    Provansal, Magalie
    Sabatier, Renaud
    Sabiani, Laura
    Blache, Guillaume
    Jauffret, Camille
    Ferre, Marjorie
    Mailleux, Hugues
    Paciencia, Maria
    Tallet, Agnes
    [J]. GYNECOLOGIC ONCOLOGY, 2021, 161 (01) : 166 - 172
  • [2] THE IMPACT OF MODERN PREOPERATIVE HIGH-DOSE-RATE BRACHYTHERAPY IN EARLY-STAGE CERVICAL CANCER
    Cagetti, Leonel Varela
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A4 - A4
  • [3] An analysis of simulation for adjuvant intracavitary high-dose-rate brachytherapy in early-stage endometrial cancer
    Barney, Brandon M.
    MacDonald, O. Kenneth
    Lee, Christopher M.
    Rankin, Jim
    Gaffney, David K.
    [J]. BRACHYTHERAPY, 2007, 6 (03) : 201 - 206
  • [4] High-dose-rate brachytherapy as sole modality for early-stage endobronchial carcinoma
    Marsiglia, H
    Baldeyrou, P
    Lartigau, E
    Briot, E
    Haie-Meder, C
    Le Chevalier, T
    Sasso, G
    Gerbaulet, A
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (03): : 665 - 672
  • [5] High-dose-rate brachytherapy in early oral cancer with close or positive margins
    Petera, Jiri
    Sirak, Igor
    Laco, Jan
    Kasaova, Linda
    Tucek, Lubos
    Doezalova, Helena
    [J]. BRACHYTHERAPY, 2015, 14 (01) : 77 - 83
  • [6] Acute Toxicity of High-Dose-Rate Intracavitary Brachytherapy With the MammoSite Applicator in Patients With Early-Stage Breast Cancer
    Gregory M. Richards
    Anthony M. Berson
    John Rescigno
    Seema Sanghavi
    Beth Siegel
    Deborah Axelrod
    Stephanie Bernik
    Vincent Scarpinato
    Christopher Mills
    [J]. Annals of Surgical Oncology, 2004, 11 : 739 - 746
  • [7] Acute toxicity of high-dose-rate intracavitary brachytherapy with the MarnmoSite applicator in patients with early-stage breast cancer
    Richards, GM
    Berson, AM
    Rescigno, J
    Sanghavi, S
    Siegel, B
    Axelrod, D
    Bernik, S
    Scarpinato, V
    Mills, C
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (08) : 739 - 746
  • [8] High dose rate brachytherapy for early stage oral tongue cancer
    Leung, TW
    Wong, VYW
    Kwan, KH
    Ng, TY
    Wong, CM
    Tung, SY
    Leung, LC
    O, SK
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2002, 24 (03): : 274 - 281
  • [9] Clinically evident fat necrosis in women treated with high-dose-rate brachytherapy alone for early-stage breast cancer
    Wazer, DE
    Lowther, D
    Boyle, T
    Ulin, K
    Neuschatz, A
    Ruthazer, R
    DiPetrillo, TA
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 50 (01): : 107 - 111
  • [10] Image-guided high-dose-rate brachytherapy as the method of choice in medically inoperable early-stage endometrial cancer patients
    Rydzinski, Martin
    Bijok, Michal
    Michalski, Wojciech
    Kowalczyk, Adam
    Gruszczynska, Ewelina
    Zolciak-Siwinska, Agnieszka
    [J]. GYNECOLOGIC ONCOLOGY, 2024, 180 : 6 - 13